These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22844127)

  • 1. Utility of inflammation-based prognostic scoring in patients given systemic chemotherapy first-line for advanced inoperable bladder cancer.
    Hwang EC; Hwang IS; Yu HS; Kim SO; Jung SI; Hwang JE; Kang TW; Kwon DD; Park K; Ryu SB
    Jpn J Clin Oncol; 2012 Oct; 42(10):955-60. PubMed ID: 22844127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy.
    Hsieh MC; Chiang PH; Rau KM; Chen YY; Su YL; Huang CH
    Urol Oncol; 2015 Nov; 33(11):495.e9-495.e14. PubMed ID: 26254698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of weekly docetaxel, cisplatin, and 5-fluorouracil for locally advanced or metastatic gastric cancer patients with ECOG performance scores of 1 and 2.
    Turkeli M; Aldemir MN; Cayir K; Simsek M; Bilici M; Tekin SB; Yildirim N; Bilen N; Makas I
    Asian Pac J Cancer Prev; 2015; 16(3):985-9. PubMed ID: 25735393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy.
    Li QQ; Lu ZH; Yang L; Lu M; Zhang XT; Li J; Zhou J; Wang XC; Gong JF; Gao J; Li J; Li Y; Shen L
    Asian Pac J Cancer Prev; 2014; 15(2):945-50. PubMed ID: 24568523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
    Halim A; Abotouk N
    Asia Pac J Clin Oncol; 2013 Mar; 9(1):60-5. PubMed ID: 22897883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.
    Hurwitz HI; Uppal N; Wagner SA; Bendell JC; Beck JT; Wade SM; Nemunaitis JJ; Stella PJ; Pipas JM; Wainberg ZA; Manges R; Garrett WM; Hunter DS; Clark J; Leopold L; Sandor V; Levy RS
    J Clin Oncol; 2015 Dec; 33(34):4039-47. PubMed ID: 26351344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment and prognosis of 117 patients with advanced urothelial carcinoma of the bladder].
    Song Y; Yang L; Zhou A; Chi Y; Wang J
    Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):212-6. PubMed ID: 24785283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin.
    Saito K; Urakami S; Komai Y; Yasuda Y; Kubo Y; Kitsukawa S; Okubo Y; Yamamoto S; Yonese J; Fukui I
    BJU Int; 2012 Nov; 110(10):1478-84. PubMed ID: 22520732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.
    Novarino AM; Satolli MA; Chiappino I; Giacobino A; Napoletano R; Ceccarelli M; Ciccone G; Schena M; Bertetto O; Ciuffreda L
    Am J Clin Oncol; 2013 Oct; 36(5):466-71. PubMed ID: 22781390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer.
    Hwang JE; Kim HN; Kim DE; Choi HJ; Jung SH; Shim HJ; Bae WK; Hwang EC; Cho SH; Chung IJ
    BMC Cancer; 2011 Nov; 11():489. PubMed ID: 22103888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Glasgow Prognostic Score predicts poor survival in cisplatin-based treated patients with metastatic nasopharyngeal carcinoma.
    Chen C; Sun P; Dai QS; Weng HW; Li HP; Ye S
    PLoS One; 2014; 9(11):e112581. PubMed ID: 25393117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases.
    Brandi G; Derenzini E; Falcone A; Masi G; Loupakis F; Pietrabissa A; Pinna AD; Ercolani G; Pantaleo MA; Di Girolamo S; Grazi GL; de Rosa F; Biasco G
    Clin Colorectal Cancer; 2013 Sep; 12(3):188-94. PubMed ID: 23773458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
    Hwang I; Kang J; Ip HNN; Jeong JH; Kim KP; Chang HM; Yoo C; Ryoo BY
    Invest New Drugs; 2019 Jun; 37(3):584-590. PubMed ID: 30324344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
    Ecke TH; Bartel P; Koch S; Ruttloff J; Theissig F
    Oncol Rep; 2006 Dec; 16(6):1381-8. PubMed ID: 17089065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study.
    Inal A; Kaplan MA; Kuçukoner M; Urakci Z; Guven M; Nas N; Yunce M; Işikdogan A
    Asian Pac J Cancer Prev; 2012; 13(8):3869-72. PubMed ID: 23098485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients.
    Chen LK; Liang Y; Yang QY; Xu F; Zhou NN; Xu GC; Liu GZ; Wei WD
    Asian Pac J Cancer Prev; 2012; 13(5):1863-7. PubMed ID: 22901137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study.
    El-Hadaad HA; Wahba HA
    J Gastrointest Cancer; 2013 Sep; 44(3):313-7. PubMed ID: 23606201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine plus nedaplatin as salvage therapy is a favorable option for patients with progressive metastatic urothelial carcinoma after two lines of chemotherapy.
    Matsumoto K; Mochizuki K; Hirayama T; Ikeda M; Nishi M; Tabata K; Okazaki M; Fujita T; Taoka Y; Iwamura M
    Asian Pac J Cancer Prev; 2015; 16(6):2483-7. PubMed ID: 25824784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.
    Linardou H; Aravantinos G; Efstathiou E; Kalofonos C; Anagnostopoulos A; Deliveliotis C; Bafaloukos D; Athanasios Dimopoulos M; Bamias A;
    Urology; 2004 Sep; 64(3):479-84. PubMed ID: 15351574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer.
    Leung EY; Scott HR; McMillan DC
    J Thorac Oncol; 2012 Apr; 7(4):655-62. PubMed ID: 22425914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.